These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 16076816)

  • 21. [Oncogenes and pharmacological approaches to cancer therapy].
    Tocque B
    Pathol Biol (Paris); 1992 Nov; 39(9):869-70. PubMed ID: 1538914
    [No Abstract]   [Full Text] [Related]  

  • 22. Targeting transcription factors for cancer therapy.
    Redell MS; Tweardy DJ
    Curr Pharm Des; 2005; 11(22):2873-87. PubMed ID: 16101443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense therapy in cancer.
    Pawlak W; Zolnierek J; Sarosiek T; Szczylik C
    Cancer Treat Rev; 2000 Oct; 26(5):333-50. PubMed ID: 11006135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The c-myb proto-oncogene: a novel target for human gene therapy.
    Gewirtz AM
    Cancer Treat Res; 1996; 84():93-112. PubMed ID: 8724627
    [No Abstract]   [Full Text] [Related]  

  • 25. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis.
    Kusaba M; Nakao K; Goto T; Nishimura D; Kawashimo H; Shibata H; Motoyoshi Y; Taura N; Ichikawa T; Hamasaki K; Eguchi K
    J Hepatol; 2007 Oct; 47(4):546-55. PubMed ID: 17602782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity.
    Buettner R; Huang M; Gritsko T; Karras J; Enkemann S; Mesa T; Nam S; Yu H; Jove R
    Mol Cancer Res; 2007 Aug; 5(8):823-32. PubMed ID: 17699108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer.
    Haura EB; Turkson J; Jove R
    Nat Clin Pract Oncol; 2005 Jun; 2(6):315-24. PubMed ID: 16264989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
    Tan M; Lan KH; Yao J; Lu CH; Sun M; Neal CL; Lu J; Yu D
    Cancer Res; 2006 Apr; 66(7):3764-72. PubMed ID: 16585203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of STAT3 antisense oligodeoxynucleotides on apoptosis and proliferation of mouse melanoma cell line B16].
    Tang GS; Cai JM; Ni J; Xiang YS; Cui JG; Zhu D; Dong JR
    Ai Zheng; 2006 Mar; 25(3):269-74. PubMed ID: 16536977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
    Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
    Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
    Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
    Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides.
    Weerasinghe P; Garcia GE; Zhu Q; Yuan P; Feng L; Mao L; Jing N
    Int J Oncol; 2007 Jul; 31(1):129-36. PubMed ID: 17549413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression patterns of fatty acid binding proteins in breast cancer cells.
    Hammamieh R; Chakraborty N; Barmada M; Das R; Jett M
    J Exp Ther Oncol; 2005; 5(2):133-43. PubMed ID: 16471039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkappaB kinase/nuclear factor-kappaB pathway.
    Ciucci A; Gianferretti P; Piva R; Guyot T; Snape TJ; Roberts SM; Santoro MG
    Mol Pharmacol; 2006 Nov; 70(5):1812-21. PubMed ID: 16908599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids.
    Selvendiran K; Koga H; Ueno T; Yoshida T; Maeyama M; Torimura T; Yano H; Kojiro M; Sata M
    Cancer Res; 2006 May; 66(9):4826-34. PubMed ID: 16651438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic oligonucleotides: the road not taken.
    Stein CA; Goel S
    Clin Cancer Res; 2011 Oct; 17(20):6369-72. PubMed ID: 21862637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antisense against cancer?]].
    Edris E; Möller AM; Oberhauser EM; Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2010 May; 39(3):170-1. PubMed ID: 20425764
    [No Abstract]   [Full Text] [Related]  

  • 38. Hybridon and Aegera collaborate to develop antisense drug.
    Expert Rev Anticancer Ther; 2002 Oct; 2(5):483-4. PubMed ID: 12382515
    [No Abstract]   [Full Text] [Related]  

  • 39. American Association for Cancer Research--94th Annual Meeting. New compounds. 11-14 July 2003, Washington, DC, USA.
    Mackay J; Williams L
    IDrugs; 2003 Aug; 6(8):733-5. PubMed ID: 12971387
    [No Abstract]   [Full Text] [Related]  

  • 40. [Perspectives of the use of informational drugs in cancer].
    Gutiérrez AA; Angel Sánchez L; Mas-Oliva J
    Gac Med Mex; 1995; 131(4):481-4. PubMed ID: 8948912
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.